Lifeboat Foundation

Recorded Oct 4th, 2017

Link to the interview, goo.gl/8rQ6YS

Continue reading “Aubrey de Grey, Ph.D.: Rejuvenation biotechnology: Why Age May Soon Not Mean Aging” »

A new study suggests that cancer cells trick normal cells to produce virus-like particles that help tumor cells to grow and spread.

The work, published in the March 8 issue of Science, finally proves that a single anti-aging enzyme in the body can be targeted, with the potential to prevent age-related diseases and extend lifespans.

The paper shows all of the 117 drugs tested work on the single enzyme through a common mechanism. This means that a whole new class of anti-aging drugs is now viable, which could ultimately prevent cancer, Alzheimer’s disease and type 2 diabetes.

“Ultimately, these drugs would treat one disease, but unlike drugs of today, they would prevent 20 others,” says the lead author of the paper, Professor David Sinclair, from UNSW Medicine, who is based at Harvard University. “In effect, they would slow aging.”

Continue reading “Anti-aging drug breakthrough” »

There’s no doubt that Dr. Ilia Stambler’s Longevity promotion: multidisciplinary perspective is a great book for the advocate and keen supporter of healthy life extension. Check out our review by Nicola Bagalà.

There’s no doubt that Dr. Ilia Stambler’s Longevity promotion: multidisciplinary perspective is a thorough book that all kinds of advocates of healthy longevity may find very useful. The book reads pretty much like a collection of academics papers, each dealing with a different aspect of the matter, including science, history, social and moral implications, legislation, and advocacy. Just like you would expect from an academic work, each section of this book is complete with exhaustive sources that will indubitably prove helpful should you wish to dig deeper into the topic being discussed.

The first section of the book focuses on advocacy, discussing typical concerns raised in the context of life extension, outreach material, and initiatives, and it offers suggestions for effective policies to promote aging and longevity research. The latter part of this section was one of the hardest for me to read since policies and legislation are not at all my strongest suit, but I do believe that professional lobbyists and advocates who have legal and regulatory backgrounds and wish to take action will find numerous ideas in it.

Continue reading “Book Review: Longevity Promotion a Multidisciplinary Perspective” »

Summary: Funding bias is junk science used by industry to hoodwink consumers. This report shows you how to protect yourself against the problem.

The funding bias scandal made headlines recently when the Journal of the American Medical Association (JAMA) broke the news that the sugar industry had paid-off Harvard scientists to down-play sugars role in heart disease. JAMA reported that the sugar industry trade group called the Sugar Research Foundation instructed Harvard researchers to publish reports that down-played sugar’s connection to heart disease, and instead cast doubts on saturated fat.

And in another study, after examining over 200 research studies paid for by a food or beverage organization, researchers from Children’s Hospital Boston found that industry-funded studies were four to eight times more likely to report positive health benefits from consuming those products.

1 in 3 American adults has prediabetes and 90% don’t know it. Prediabetes treatment adds years to your life and prevents type 2 diabetes.

A growing body of evidence shows that coffee prevents type 2 diabetes.

Type 2 diabetes is a massive health problem that’s about to get worse. A recent study concluded that 40% of Americans alive today are expected to get the disease. Left untreated, the soaring blood sugar caused by type 2 diabetes creates serious health problems throughout the body, including heart disease, stroke, loss of limbs, kidney failure, blindness, and double the risk of death.

Research has shown that drinking coffee is a way to prevent type 2 diabetes.

NASA’s acting chief technologist, Dr Douglas Terrier, made the comments ahead of an appearance at the Codex innovation summit, held in London.

One of the techniques currently under development that it is following is NMN, a compound expected to enter clinical trials after it was shown to rejuvenate elderly mice in laboratory tests.

Continue reading “NASA may alter the DNA of astronauts who journey to Mars” »